Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod pretreatment before Mohs surgery for large facial nodular basal cell carcinoma
NL-OMON31041Not yet recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- May 2007
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of imiquimod in basal cell carcinoma (BCC) (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoint: Defect size after Mohs micrographic surgery. Planned start May 2007; status: not yet recruiting.
02
Drugs
imiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON31041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31041.